FDA
The FDA and CDC will soon decide on Pfizer-BioNTech’s request for an Emergency Use Authorization for the booster shot for their COVID-19 vaccine.
FEATURED STORIES
A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the “ideal fit” to stabilize the agency. And, according to one ex-FDA official, if his CBER counterpart Vinay Prasad tries to supersede Pazdur’s authority, “there will be hell to pay.”
Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and feasibility of the Commissioner’s National Priority Voucher program.
Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Clovis Oncology’s Rubraca remained the only PARP inhibitor approved for prostate cancer for only a handful of days. Today, that medication is joined by AstraZeneca’s and Merck’s powerhouse PARP inhibitor, Lynparza.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
The approval was based on interim analysis from the company’s Phase III IMpower110 trial.
With the new approval, Rubraca becomes the first PARP inhibitor approved in a prostate cancer setting.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 13, 2020.